Aptevo Therapeutics Inc. (APVO)

1.3500 +0.0100 (+0.75%)

At close: 4:00:00 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate

Zacks Small Cap Research 6d ago

APVO
+3.73%
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

ACCESS Newswire 7d ago

APVO
+3.73%
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

ACCESS Newswire 19d ago

APVO
+3.73%
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

ACCESS Newswire 1mo ago

APVO
+3.73%
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML

InvestorsHub 1mo ago

APVO
+3.73%
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

ACCESS Newswire 1mo ago

APVO
+3.73%
APVO: Focusing on Three Key Areas of Development

Zacks Small Cap Research 2mo ago

APVO
+3.73%
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

ACCESS Newswire 2mo ago

APVO
+3.73%
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

ACCESS Newswire 2mo ago

APVO
+3.73%
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

ACCESS Newswire 3mo ago

APVO
+3.73%
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

ACCESS Newswire 4mo ago

APVO
+3.73%
APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement

Zacks Small Cap Research 4mo ago

APVO
+3.73%

Performance Overview

Return	APVO	S&P 500 (^GSPC)
YTD	-85.68%	+10.17%
1-Year	-95.16%	+10.25%
3-Year	-100.00%	+74.66%

U.S. markets closed

Aptevo Therapeutics Inc. (APVO)

APVO: Mipletamig Combination Therapy Leads to 21% Stem Cell Transplantation Rate

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

APVO: Focusing on Three Key Areas of Development

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement